FTH Faeth Therapeutics, Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
FTH
—
—
What changed
Recent filings, trades and moves- Nov 9 8-K: Other events
- Nov 9 8-K: Regulation FD disclosure
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 29
- List Date
- 2021-02-04
- CIK
- 0001829802
- Last Earnings
- Aug 4
- Next Earnings
- ~Nov 13, 2026 (estimated)
- Headquarters
- Austin, TX
- Homepage
- https://www.faeththerapeutics.com
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | -- | -- |
| Mar | -- | -- |
| Apr | -- | -- |
| May | -- | -- |
| Jun | 72.06% | 72.06% |
| Jul | 14.12% | 14.12% |
| Aug | 19.86% | 19.86% |
| Sep | -13.82% | -13.82% |
| Oct | -33.89% | -33.89% |
| Nov | -32.81%* | -32.81% |
| Dec | -- | -- |
| Total | -9.91% | -9.91% |
* Only 1 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $18.82
SMA 50: $26.64
SMA 200: —
Current: $12.92
EMA 12: $18.04
EMA 26: $20.61
MACD: -2.5728 | Signal: -0.1005
BEARISH
ADX (14): 27.51
TREND
+DI: 14.53
−DI: 37.59
Momentum Oscillators
RSI (14): 29.39
OVERSOLD
Stoch %K: 46.84
Stoch %D: 60.79
Williams %R: -78.71
Volume & Volatility
BB Upper: $23.45
BB Lower: $14.19
OVERSOLD
OBV: -6,575,716
Vol SMA 20: 620,190
Vol ROC: 126.13%
ATR: $2.77
True Range: $2.13
HV 20: 221.4%
HV 30: 185.5%
HV 60: 142.3%
Data Summary
Data Points: 103
Last Updated:
Date Range: 2026-06-16T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Here is a comprehensive stock analysis report for FTH:
Executive Summary
- Overall assessment: NEUTRAL (6/10)
- Key drivers and primary risks: Earnings announcements, FDA approvals, product launches
- 2-3 sentence investment thesis: FTH's recent price action has been characterized by consolidation, with the stock hovering around its SMA 50 level. The technical indicators suggest a neutral sentiment, while the news sentiment is positive.
- Recent news sentiment impact: Positive news from DelveInsight on Advanced Endometrial Cancer Clinical Trial Pipeline Analysis has contributed to the overall bullish sentiment.
Technical Analysis
- Trend Direction: Short-term (1-4 weeks): Consolidation; Medium-term (1-3 months): Uptrend; Long-term (3-12 months): Uptrend
- Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- SMA 20: $34.19 (support)
- EMA 12: $36.05 (resistance)
- Upper Bollinger Band: $40.31 (resistance)
- Momentum Signals:
- RSI interpretation: Neutral (58.53) - not oversold or overbought
- MACD signal: Bullish (Histogram: 2.30)
- Bollinger Bands position: Squeeze (neutral)
- Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 298236.30 (medium volume)
- On-Balance Volume (OBV): 45979.03 (positive OBV trend)
News & Sentiment Analysis
- Recent Headlines Summary: Key themes from last 10 news articles: Positive sentiment on Advanced Endometrial Cancer Clinical Trial Pipeline Analysis
- Sentiment Assessment: Aggregate news sentiment: POSITIVE
- Catalyst Identification: Upcoming events, earnings, product launches, regulatory changes:
- Earnings announcements (no specific dates available)
- FDA approvals or product launches (no specific dates available)
- Market Narrative: News aligns with technical signals - positive sentiment and consolidation
Risk & Volatility Assessment
- Beta Interpretation: Risk relative to market: Low volatility - stock moves less than market
- Volatility Regime: Current vs historical volatility levels:
- Average True Range (ATR): $3.25 (low volatility)
- Historical Volatility: HV20 83.7%, HV30 88.4% (medium-high volatility)
- Options Market Signals: IV Premium vs HV30: N/A (positive = implied richer than realized)
- Downside Protection: Support levels and risk management considerations:
- SMA 50: $30.44 (support)
Market Context & Positioning
- Sector Performance: Relative strength vs sector/market: Not available
- Institutional Activity: Volume patterns suggesting institutional interest signals: Medium volume and positive OBV trend
- Correlation Analysis: How stock moves relative to market (R-squared interpretation): Not available
- Relative Valuation: Position within trading range:
- Relative to SMA 50: Neutral
Key Levels & Action Items
- Critical Price Levels: Support/resistance to monitor:
- SMA 20: $34.19 (support)
- EMA 12: $36.05 (resistance)
- Upper Bollinger Band: $40.31 (resistance)
- Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- SMA 50: $30.44 (breakdown risk)
- Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- Earnings announcements (no specific dates available)
- FDA approvals or product launches (no specific dates available)
- Risk Management: Stop-loss levels and position sizing considerations:
- Set stop-loss below SMA 50 ($30.44) for downside protection
Please note that this analysis is based on the provided data, and it's essential to consider additional factors before making an investment decision.
Generated
News
All FTH news →
Biotech stock Faeth Therapeutics crashed Monday as investors questioned the effectiveness of its endometrial cancer drug. The post Faeth Therapeutics Plummets 42%. What Investors Are Getting Wrong, According To Analysts. appeared first on Investor's Business Daily .
FTH Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: -0.6799
Alpha: 59.67%
Correlation: -0.0740
R-Squared: 0.5%
Stock Volatility: 127.9%
Market Volatility: 13.9%
Analysis Details
Benchmark: SPY
Data Points: 102
Period: 252 trading days
Data Points: 102
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
Notable investors who own FTH
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $510K | #2605 of 3138 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $307K | #5043 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
FTH Institutional Ownership (13F)
Filings for 2026-06-30 · 11 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
FTH Insider Trading (Form 4)
Latest: 2026-11-03Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-03 | Anand Kiran Parikh | President and CEO | Gift (G) | — | — | EDGAR | |
| 2026-10-27 | Adam Schayowitz | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-09-15 | Karen H Vousden | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-07-23 | Josiah Craver | PAO | Grant (A) | +30,824 opt | — | EDGAR | |
| 2026-07-23 | Anand Kiran Parikh | President and CEO | Grant (A) | +398,018 opt | — | EDGAR | |
| 2026-07-01 | Brian C Stephenson | Chief Financial Officer | Buy (P) | +13,634 | $23.92 | $326.1K | EDGAR |
| 2026-06-26 | Brian C Stephenson | Chief Financial Officer | Buy (P) | +15,641 | $25.65 | $401.3K | EDGAR |
| 2026-06-24 | Anand Kiran Parikh | President and CEO | Mixed Buy +2,806 · Exer +53,465 |
+56,271 | $2.09 | $117.5K | EDGAR |
| 2026-06-24 | Brian C Stephenson | Chief Financial Officer | Buy (P) | +17,413 | $23.31 | $405.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
FTH Insider Holdings
2 insiders · @ $12.92
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Anand Kiran Parikh | President and CEO | 817,699 | $10.56M | $55.4K | 3 | 2026-11-03 |
| 2 | Brian C Stephenson | Chief Financial Officer | 35,795 | $462.5K | $1.13M | 3 | 2026-07-01 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
FTH Board & Officers
As of SEC filings through Nov 3, 2026Directors 9
- Bob Holmen · since Feb 3, 2021
- John Celebi · since Feb 3, 2021
- William R Ringo · since Mar 8, 2022
- Phillip B. Donenberg · since Feb 13, 2026
- Anand Kiran Parikh · since Feb 17, 2026
- Saira Ramasastry · since Jun 12, 2026
- Stephen M. Hahn · since Jun 12, 2026
- Karen H Vousden · since Sep 11, 2026
- Adam Schayowitz · since Oct 23, 2026
Officers 4
- Anand Kiran Parikh · President and CEO · listed since Jun 2026
- Christopher Gerry · President & PEO · since Nov 14, 2025
- Brian C Stephenson · Chief Financial Officer · since Jun 13, 2026
- Josiah Craver · Principal Financial Officer · since Sep 17, 2024
10% owners 6
- Khosla Ventures Associates VI, LLC (entity) · since Jun 15, 2026
- Khosla Ventures Seed Associates D, LLC (entity) · since Jun 15, 2026
- Khosla Ventures Seed D, L.P. (entity) · since Jun 15, 2026
- Khosla Ventures VI, L.P. (entity) · since Jun 15, 2026
- VK Services, LLC (entity) · since Jun 15, 2026
- Vinod Khosla · since Jun 15, 2026
Changes in the last 10 years (69)
| Oct 23, 2026 | Adam Schayowitz became a director |
| Sep 11, 2026 | Karen H Vousden became a director |
| Jun 16, 2026 | Anand Kiran Parikh listed as President and CEO (previously Chief Operating Officer) in SEC filings |
| Jun 15, 2026 | Vinod Khosla became a 10% owner |
| Jun 15, 2026 | VK Services, LLC became a 10% owner |
| Jun 15, 2026 | Khosla Ventures VI, L.P. became a 10% owner |
| Jun 15, 2026 | Khosla Ventures Seed D, L.P. became a 10% owner |
| Jun 15, 2026 | Khosla Ventures Seed Associates D, LLC became a 10% owner |
| Jun 15, 2026 | Khosla Ventures Associates VI, LLC became a 10% owner |
| Jun 13, 2026 | Brian C Stephenson became Chief Financial Officer |
| Jun 12, 2026 | Stephen M. Hahn became a director |
| Jun 12, 2026 | Saira Ramasastry became a director |
| Jun 1, 2026 | James Peyer reported in an SEC filing no longer being a 10% owner |
| Jun 1, 2026 | Cambrian BioPharma Inc reported in an SEC filing no longer being a 10% owner |
| May 15, 2026 | Millennium Management LLC reported in an SEC filing no longer being a 10% owner |
| May 15, 2026 | Millennium Group Management LLC reported in an SEC filing no longer being a 10% owner |
| May 15, 2026 | Israel A Englander reported in an SEC filing no longer being a 10% owner |
| May 15, 2026 | Ics Opportunities II LLC reported in an SEC filing no longer being a 10% owner |
| Apr 10, 2026 | The company announced the departure of Thomas G Ricks from the board in an SEC filing |
| Apr 10, 2026 | The company announced the departure of Kristian Humer from the board in an SEC filing |
| Mar 26, 2026 | Millennium Management LLC became a 10% owner |
| Mar 26, 2026 | Millennium Group Management LLC became a 10% owner |
| Mar 26, 2026 | Israel A Englander became a 10% owner |
| Mar 26, 2026 | Ics Opportunities II LLC became a 10% owner |
| Feb 17, 2026 | Anand Kiran Parikh became a director |
| Feb 17, 2026 | Anand Kiran Parikh became Chief Operating Officer |
| Feb 13, 2026 | Phillip B. Donenberg became a director |
| Dec 8, 2025 | James Peyer no longer listed as a director in SEC filings |
| Nov 14, 2025 | Christopher Gerry became President & PEO |
| Oct 25, 2024 | The company announced the departure of Deneen Vojta from the board in an SEC filing |
| Sep 17, 2024 | The company announced the departure of David G Gaiero as Principal Financial Officer in an SEC filing |
| Sep 17, 2024 | Josiah Craver became Principal Financial Officer |
| Jun 26, 2024 | The company announced the departure of Jessie English from the board in an SEC filing |
| May 10, 2024 | David G Gaiero became Principal Financial Officer |
| Mar 27, 2024 | The company announced the departure of Erin Colgan as Chief Financial Officer in an SEC filing |
| Feb 5, 2024 | The company announced the departure of Samuel Broder from the board in an SEC filing |
| Nov 1, 2023 | Stephanie Krebs became Chief Business Officer |
| Sep 11, 2023 | Patrick Stephen Gallagher reported in an SEC filing no longer being Chief Business Officer |
| Jun 2, 2023 | Presight Co-Invest Management, L.L.C. reported in an SEC filing no longer being a 10% owner |
| Jun 2, 2023 | Christian Angermayer reported in an SEC filing no longer being a 10% owner |
| Jun 2, 2023 | Apeiron Investment Group Ltd. reported in an SEC filing no longer being a 10% owner |
| Dec 7, 2022 | Horst Edward van der became Chief Scientific Officer |
| Jul 14, 2022 | Presight Co-Invest Management, L.L.C. became a 10% owner |
| Jul 14, 2022 | Christian Angermayer became a 10% owner |
| Jul 14, 2022 | Apeiron Investment Group Ltd. became a 10% owner |
| Jun 1, 2022 | Patrick Stephen Gallagher became Chief Business Officer |
| Mar 8, 2022 | William R Ringo became a director |
| Feb 17, 2022 | Robert Hamilton Pierce listed as Chief R&D Officer (previously Chief Scientific Officer) in SEC filings |
| Feb 17, 2022 | Erin Colgan listed as Chief Financial Officer (previously SVP of Finance) in SEC filings |
| Jul 30, 2021 | Kristian Humer became a director |
| Apr 1, 2021 | Jessie English became a director |
| Feb 3, 2021 | Thomas G Ricks became a director |
| Feb 3, 2021 | Susan Samueli became a 10% owner |
| Feb 3, 2021 | Samuel Broder became a director |
| Feb 3, 2021 | Robert Hamilton Pierce became Chief Scientific Officer |
| Feb 3, 2021 | Michael Schulman became a 10% owner |
| Feb 3, 2021 | Marie-Louise Fjaellskog became Chief Medical Officer |
| Feb 3, 2021 | John Celebi became a director |
| Feb 3, 2021 | John Celebi became President and CEO |
| Feb 3, 2021 | James Peyer became a director |
| Feb 3, 2021 | James Peyer became a 10% owner |
| Feb 3, 2021 | Henry Samueli became a 10% owner |
| Feb 3, 2021 | H&s Ventures LLC became a 10% owner |
| Feb 3, 2021 | H&s Investments I LP became a 10% owner |
| Feb 3, 2021 | Erin Colgan became SVP of Finance |
| Feb 3, 2021 | Deneen Vojta became a director |
| Feb 3, 2021 | Cambrian BioPharma Inc became a 10% owner |
| Feb 3, 2021 | Bob Holmen became a director |
| Feb 3, 2021 | Anupama Hoey became Chief Business Officer |
Not reported recently (10)
- Horst Edward van der · Last reported as Chief Scientific Officer in an SEC filing dated Feb 26, 2025
- Stephanie Krebs · Last reported as Chief Business Officer in an SEC filing dated Feb 14, 2025
- Robert Hamilton Pierce · Last reported as Chief R&D Officer in an SEC filing dated Sep 1, 2022
- Susan Samueli · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
- Michael Schulman · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
- Henry Samueli · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
- H&s Investments I LP · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
- H&s Ventures LLC · Last reported as a 10% owner in an SEC filing dated Feb 10, 2021
- Anupama Hoey · Last reported as Chief Business Officer in an SEC filing dated Feb 5, 2021
- Marie-Louise Fjaellskog · Last reported as Chief Medical Officer in an SEC filing dated Feb 5, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
FTH Proposed Insider Sales (Form 144)
Latest: 2026-08-11
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $3.6M notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Cambrian BioPharma Inc (1, $3.6M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Cambrian BioPharma Inc | 10% Stockholder | 130,142 | $3.64M | 2026-07-22 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-04-29 | Cambrian BioPharma Inc | 10% Stockholder | 155,142 | $4.96M | 2026-04-29 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-24 | Celebi John | Former Officer | 3,374 | $116.4K | 2026-02-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-18 | Peyer James | Fomer Director | 950 | $25.8K | 2026-02-18 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-01-27 | RINGO WILLIAM R | Former Director | 1,169 | $11.5K | 2026-01-27 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-12-09 | Peyer James | Former Director | 841 | $6.7K | 2025-12-09 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-12-04 | Cambrian BioPharma Inc | 10% Stockholder | 5,844 | $50.9K | 2025-12-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-12-04 | Cambrian BioPharma Inc | 10% Stockholder | 21,222 | $184.8K | 2025-12-04 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-09
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-09 | Other events | EDGAR |
| 2026-11-09 | Regulation FD disclosure | EDGAR |
| 2026-11-03 | Earnings results | EDGAR |
| 2026-10-27 | Director or officer change | EDGAR |
| 2026-09-17 | Director or officer change | EDGAR |
| 2026-08-04 | Earnings results | EDGAR |
| 2026-07-23 | Director or officer change | EDGAR |
| 2026-06-18 | Material agreement · Other events | EDGAR |
| 2026-06-15 | Agreement terminated · Director or officer change · Bylaws or fiscal year change · Regulation FD disclosure · Other events | EDGAR |
| 2026-06-10 | Director or officer change · Bylaws or fiscal year change · Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
8 ETFs hold FTH
8 shown · $35.31M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $21.0M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $6.6M | — | 2026-09-30 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.05% | $4.9M | $10.3B | 2026-11-06 |
| 4 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.14% | $1.6M | $1.2B | 2026-11-06 |
| 5 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $651,908 | $95.6B | 2026-11-06 |
| 6 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $202,838 | $10.1B | 2026-11-06 |
| 7 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.03% | $181,207 | — | 2026-11-09 |
| 8 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $105,223 | $3.2B | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
FTH vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ABBV ABBVIE INC. | $518.4B | 50.6 | +10.7% | +28.2% | 33 |
| AMGN Amgen Inc | $251.6B | 27.0 | +8.2% | +42.0% | 36 |
| GILD Gilead Sciences Inc | $210.0B | — | +6.5% | +40.5% | 43 |
| MRNA Moderna, Inc. Common Stock | $108.8B | — | −27.6% | +712.8% | 47 |
| REGN Regeneron Pharmaceuticals Inc | $95.2B | 20.2 | +18.6% | +18.0% | 54 |
| BIIB Biogen Inc. Common Stock | $37.7B | 108.2 | +2.3% | +42.4% | 97 |
| EXEL Exelixis Inc | $17.5B | 21.1 | +9.1% | +62.0% | 19 |
| HALO Halozyme Therapeutics, Inc. | $11.7B | 30.0 | +41.2% | +46.5% | 49 |
| FTH Faeth Therapeutics, Inc. Common Stock | $328M | — | — | −11.1% | — |
| Peer median | $102.0B | 28.5 | +8.6% | +42.2% | 45 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.